We are on a mission to radically improve disease diagnoses and treatments, helping people live longer, healthier lives.

With PET, the barriers to better imaging are largely the result of basic limitations in chemistry. Leveraging a breakthrough in alkali metal catalysis, Fuzionaire Dx is working to radically improve the scope, safety, use, and cost of PET imaging.

Fuzionaire Dx is a radiopharmaceutical company. Our radiolabeling platform aims to unlock the power of PET to help detect and treat any disease and improve the drug discovery process.

We make it possible to rapidly produce a broad range of fluorine-18 radiopharmaceuticals based on a single, catalyst-driven, disease-agnostic platform. Our technology offers researchers and clinicians a new strategy to detect, localize, diagnose, and monitor more diseases, earlier, and with unprecedented precision.

The platform also has the potential to become a unique tool for drugmakers, providing critical in vivo pharmacological data earlier in the drug discovery process.

As a team of chemists, biophysicists, molecular scientists, and entrepreneurs, our mission is to unlock the power of PET to improve the human condition.

Our team

Fuzionaire is led by co-founders Nick Slavin (CEO), Anton Toutov, PhD (CSO), Nova Spivack, and a close-knit team of world-class experts advising the company.

As we enter the world of precision medicine, Fuzionaire Diagnostics provides technology that could help track and image cancers in an unprecedented way, which will ultimately allow for many novel approaches in cancer therapeutics.

Douglas Scherr, MD Professor of Oncology and Clinical Director of Urologic Oncology Weill Medical College of Cornell University

Expanding the bounds of how we diagnose, study, and treat disease

We are continuously exploring additional clinical applications of our radiolabeling platform.

  • Our heterocyclic chemistry enables radiopharmaceuticals that combine diagnostic and therapeutic approaches
  • Accelerating radiopharmaceutical discovery through combinatorial synthesis of radiotracer libraries
  • Pioneering new engineering solutions that combine flow chemistry, synthesis electrification, and automation

Get in touch

If you are interested in learning more about our radiolabeling platform, we want to hear from you.

Contact